TY - JOUR
T1 - Primary metastatic osteosarcoma
T2 - results of a prospective study in children given chemotherapy and interleukin-2
AU - Meazza, Cristina
AU - Cefalo, Graziella
AU - Massimino, Maura
AU - Daolio, Primo
AU - Pastorino, Ugo
AU - Scanagatta, Paolo
AU - Morosi, Carlo
AU - Podda, Marta
AU - Ferrari, Andrea
AU - Terenziani, Monica
AU - Spreafico, Filippo
AU - Casanova, Michela
AU - Parafioriti, Antonina
AU - Collini, Paola
AU - Gandola, Lorenza
AU - Bastoni, Stefano
AU - Biassoni, Veronica
AU - Schiavello, Elisabetta
AU - Chiaravalli, Stefano
AU - Puma, Nadia
AU - Bergamaschi, Luca
AU - Luksch, Roberto
PY - 2017/12/1
Y1 - 2017/12/1
N2 - To improve the poor prognosis for children with metastatic osteosarcoma (OS), interleukin-2 (IL-2) was added to the standard treatment due to its capacity to activate lymphocytes and differentiate lymphocyte subsets into lymphokine-activated killer (LAK) cells that are capable of recognizing and killing various tumor cells. This study concerns a cohort of unselected patients aged < 18 years with metastatic OS, who were treated with IL-2, high-dose methotrexate, doxorubicin, cisplatin, ifosfamide, LAK reinfusion, and surgery, between 1995 and 2010. Thirty-five patients aged 4–17 years were involved. Thirty-two of the 35 patients underwent surgery on their primary tumor, and 25 had surgery on lung metastases too. Twenty-seven patients received IL-2 plus LAK reinfusion. The median follow-up was 130 months (77–228), and the 3-year event-free and overall survival rates were 34.3 and 45.0%, respectively. Eleven patients remained alive, all of whom achieved a complete surgical removal of the primary tumor and lung metastases (1 patient did not receive lung resections due to complete lung metastases remission). Patients who had a complete surgical remission of the primary and metastatic sites and who responded well to chemotherapy had a better event-free survival. These results confirm the importance of complete surgical remission and point to a noteworthy (though still be ameliorate) survival rate in our series of patients, underling a potential role for immunotherapy with IL-2 and LAK/NK cell activation.
AB - To improve the poor prognosis for children with metastatic osteosarcoma (OS), interleukin-2 (IL-2) was added to the standard treatment due to its capacity to activate lymphocytes and differentiate lymphocyte subsets into lymphokine-activated killer (LAK) cells that are capable of recognizing and killing various tumor cells. This study concerns a cohort of unselected patients aged < 18 years with metastatic OS, who were treated with IL-2, high-dose methotrexate, doxorubicin, cisplatin, ifosfamide, LAK reinfusion, and surgery, between 1995 and 2010. Thirty-five patients aged 4–17 years were involved. Thirty-two of the 35 patients underwent surgery on their primary tumor, and 25 had surgery on lung metastases too. Twenty-seven patients received IL-2 plus LAK reinfusion. The median follow-up was 130 months (77–228), and the 3-year event-free and overall survival rates were 34.3 and 45.0%, respectively. Eleven patients remained alive, all of whom achieved a complete surgical removal of the primary tumor and lung metastases (1 patient did not receive lung resections due to complete lung metastases remission). Patients who had a complete surgical remission of the primary and metastatic sites and who responded well to chemotherapy had a better event-free survival. These results confirm the importance of complete surgical remission and point to a noteworthy (though still be ameliorate) survival rate in our series of patients, underling a potential role for immunotherapy with IL-2 and LAK/NK cell activation.
KW - Chemotherapy
KW - Children
KW - IL-2
KW - Lung metastases
KW - Osteosarcoma
KW - Surgery
UR - http://www.scopus.com/inward/record.url?scp=85032889188&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85032889188&partnerID=8YFLogxK
U2 - 10.1007/s12032-017-1052-9
DO - 10.1007/s12032-017-1052-9
M3 - Article
AN - SCOPUS:85032889188
VL - 34
JO - Medical Oncology
JF - Medical Oncology
SN - 1357-0560
IS - 12
M1 - 191
ER -